Author

N Saijo

Observed names: N. Saijo, Nagahiro SAIJO, Nagahiro Saijo

Institutions: Tokyo Medical University, Kindai University

Observed institutions: Tongji University, The University of Texas MD Anderson Cancer Center, Tokyo Medical University, Keio University, National Cancer Centre Japan, Shizuoka Cancer Center, Taichung Veterans General Hospital, Osaka City General Hospital, Antwerp University Hospital, Eli Lilly (Japan), Dana-Farber Cancer Institute, National Cancer Center Hospital East, National Cancer Center Hospital, National Cancer Center Research Institute, University of Duisburg-Essen, Kindai University

OpenAlex ID: A5111842962

Determinants of Response to the DNA Topoisomerase II Inhibitors Doxorubicin and Etoposide in Human Lung Cancer Cell Lines

1992 · K. Kasahara, Y. Fujiwara, et al. · JNCI Journal of the National Cancer Institute · 86

Prospective Evaluation of the Feasibility of Cisplatin‐based Chemotherapy for Elderly Lung Cancer Patients with Normal Organ Functions

1995 · Fumihiro Oshita, Takayasu Kurata, et al. · Japanese Journal of Cancer Research · 77

PDF

Determinants of Drug Response in a Cisplatin‐resistant Human Lung Cancer Cell Line

1990 · Yasuhiro Fujiwara, Yoshikazu Sugimoto, et al. · Japanese Journal of Cancer Research · 72

PDF

A randomized phase III study of irinotecan and cisplatin (CP) versus etoposide and cisplatin (EP) in extensive-disease small-cell lung cancer (ED-SCLC): Japan Clinical Oncology Group Study (JCOG 9511)

2000 · S Negoro, K Noda, et al. · Lung Cancer · 71

Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines.

1993 · T Morikage, T Ohmori, et al. · PubMed · 66

Endpoints for multimodal clinical trials in Stage III non-small cell lung cancer (NSCLC): a consensus report

1994 · M.R. Green, J.D. Cox, et al. · Lung Cancer · 36

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)

2009 · R. S. Herbst, Y. Sun, et al. · Journal of Clinical Oncology · 33

Phase I study of combination therapy with interleukin 2 and beta-interferon in patients with advanced malignancy.

1989 · T Tamura, Y Sasaki, et al. · PubMed · 30

Progress in Cancer Chemotherapy with Special Stress on Molecular-targeted Therapy

2010 · N. Saijo · Japanese Journal of Clinical Oncology · 27

Increased expression of sialyl Lewisx antigen is associated with distant metastasis in lung cancer patients: Immunohistochemical study on bronchofiberscopic biopsy specimens

1998 · Kazuya Fukuoka, Nobuhiro Narita, et al. · Lung Cancer · 27

Efficacy and Safety of Pemetrexed in Combination with Cisplatin for Malignant Pleural Mesothelioma: A Phase I/II Study in Japanese Patients

2008 · K. Nakagawa, K. Yamazaki, et al. · Japanese Journal of Clinical Oncology · 26

Docetaxel (D) versus docetaxel plus gemcitabine (DG) for second-line treatment of non-small cell lung cancer (NSCLC): Results of a JCOG randomized trial (JCOG0104)

2004 · K. Takeda, S. Negoro, et al. · Journal of Clinical Oncology · 21

Upregulated expression of angiogenesis genes and down regulation of cell cycle genes in human colorectal cancer tissue determined by cDNA macroarray.

2001 · T Tsunoda, T Nakamura, et al. · PubMed · 21

A Randomized Prospective Study of Imipenem-Cilastatin With or Without Amikacin as an Empirical Antibiotic Treatment for Febrile Neutropenic Patients

1994 · Akira Kojima, Tetsu Shinkai, et al. · American Journal of Clinical Oncology · 20

Genetic immunotherapy by intrapleural, intraperitoneal and subcutaneous injection of IL-2 gene-modified Lewis lung carcinoma cells

1997 · Yuji Heike, Minako Takahashi, et al. · International Journal of Cancer · 19

Lung Cancer Working Group Report

2010 · N. Saijo, M. Fukuoka, et al. · Japanese Journal of Clinical Oncology · 18

A phase II study of paclitaxel plus cisplatin for advanced non-small-cell lung cancer in Japanese patients

2001 · Hiroshi Sakai, Shuichi Yoneda, et al. · Cancer Chemotherapy and Pharmacology · 17

Gene Expression Profiling of Exposure to TZT-1027, a Novel Microtubule-Interfering Agent, in Non-Small Cell Lung Cancer PC-14 Cells and Astrocytes

2001 · Tsugitaka Natsume, Takashi Nakamura, et al. · Investigational New Drugs · 12

In vitro and in vivo Effects of Cisplatin and Etoposide in Combination on Small Cell Lung Cancer Cell Lines

1994 · Hideki Kondo, Fumihiko Kanzawa, et al. · Japanese Journal of Cancer Research · 12

PDF

Long-Term Survival in Patients with Small Cell Lung Cancer

1986 · J Suga, N Saijo, et al. · Japanese Journal of Clinical Oncology · 12

Effect of Glutathione Depletion on Cisplatin Resistance in Cancer Cells Transfected with the γ‐Glutamylcysteine Synthetase Gene

1997 · Hirokazu Kurokawa, Kazuto Nishio, et al. · Japanese Journal of Cancer Research · 11

PDF

A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer

1994 · Kenji Eguchi, Hisashi Etou, et al. · European Journal of Cancer · 11

[Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies].

1998 · S Yamazaki, I Sekine, et al. · PubMed · 10

Malignant germ cell tumor of the mediastinum: A multimodality therapeutic approach

1994 · Hisao Asamura, Ryosuke Tsuchiya, et al. · Surgery Today · 10

In vitro antitumor effect of recombinant human tumor necrotizing factor on cultured human cancer cell lines and freshly isolated lung cancer cells by the human tumor clonogenic assay

1987 · Yasutsuna Sasaki, Fumihiko Kanzawa, et al. · Investigational New Drugs · 8

Works count: 73

Citation count: 831

H-index: 17

I10-index: 24